Ibogaine in Kentucky

What Senate Bill 77 does, and what it lost on the way

SB 77, “AN ACT relating to ibogaine research in the Commonwealth”, was sponsored by Senator Douglas and introduced on 13 January 2026. As introduced it proposed $42 million, being $21 million in each fiscal year of the 2026-2028 biennium, drawn from the opioid abatement trust fund, to study ibogaine as a treatment for substance use disorders, with a stated future scope extending to post-traumatic stress disorder and traumatic brain injury.

That figure is the one still quoted in most coverage of the law. It is not in the law.

On 11 March the Health Services Committee reported the bill favourably with a committee substitute, and the substitute removed the appropriation, the emergency clause, and the words “making an appropriation therefor” from the title. The Senate passed the substituted bill 35 to 2 on 13 March; the House passed it 82 to 8 on 1 April. What Kentucky enacted is a framework for ibogaine research with no money attached to it.

The context is not incidental. Kentucky has been among the states worst affected by the opioid epidemic, and had previously considered directing opioid settlement money towards ibogaine research before that proposal was set aside.

The veto, and why it is the most useful part

Governor Andy Beshear vetoed SB 77 on 13 April 2026. Both chambers overrode him the following day. The legislative record gives the tallies as 31 to 6 in the Senate and 77 to 18 in the House.

His objection was not about ibogaine. It was that legislating for a single named substance, rather than for a category of candidate treatments, “raises the concern that this legislation is meant to pay a specific company”. When a state writes a cheque that only one or two entities in the world can cash, the distinction between funding research and funding a firm gets thin.

He objected on two further grounds, as the Kentucky Lantern reported: that the bill was “another instance of legislative overreach that violates the Kentucky Constitution”, and that it “would send state taxpayer dollars to companies conducting clinical trials of ibogaine”. Kentucky’s own record server does not serve the veto message itself, so this rests on reporting rather than on our reading of the document.

None of that is an argument that ibogaine research should not be funded. It is an argument about how, and it went unanswered rather than refuted: the legislature overrode the veto rather than amending the bill.

What the developer must promise on access

One provision survived the committee and is the most interesting thing in the enacted text. Section 3(2)(c) requires a contracting drug developer to establish a plan for accessible ibogaine treatment once the FDA approves a product, expressly including priority access for Kentucky residents, an effort to secure third-party payor approval, means of access for uninsured and low-income individuals, and the training and credentialing of medical providers.

Oklahoma enacted a near-identical mechanism a month later, down to the eight-category list of what counts as intellectual property. Kentucky’s definition of a drug developer also requires an agreement with at least one additional state, which puts it in the same multistate turn as Mississippi and Oklahoma.

What the developer owes the Commonwealth

Three further obligations survived the substitute:

• match the Commonwealth’s investment with an equal amount, and run the trials exclusively with in-state clinicians, facilities and study participants;
• plan to seek breakthrough therapy designation from the FDA under 21 U.S.C. 356;
• report quarterly on progress and finances, with an annual departmental report due each 1 December.

The last survivor is the state’s stake. Section 3(2)(d) requires the developer to recognise the Commonwealth’s economic interest in any intellectual property the trials generate, as a share of the proceeds proportional to what Kentucky contributed to the total cost, deposited into the fund the Act creates. Note the shape of that: a fund with no money in it, entitled to a share proportional to its contribution. Proportional to zero is zero, which is the quiet arithmetic of what the committee substitute did.

Money was stripped from this bill. The conditions on how a future medicine must be made available were not.

What SB 77 does not do

Kentucky cannot reschedule a federally controlled substance, and SB 77 does not try to. Possession remains a federal offence in Kentucky, no physician may prescribe ibogaine, and no provider may administer it outside an approved research protocol.

SB 77 buys a framework and no trials, because the money went out in committee. Even fully funded it would buy only trials, and trials are years from producing an approved medicine. Approval is the only route that ends in a treatment a Kentucky physician could offer.

Kentucky in context

Kentucky’s law is the only one so far enacted over a governor’s veto, and one of several that appropriate nothing. It is the only one where the money was voted and then taken away, which is why the $42 million still attached to Kentucky in coverage is the most durable error on this subject. Its nearest relatives are Oklahoma, which copied the mechanism a month later, and Mississippi, whose money has simply never been voted. The federal position carries the state-by-state comparison.

Colorado went further than any of them, having decriminalised personal possession by ballot measure in 2022, and funds its own pilot from donations rather than from the treasury. Texas is the instructive contrast: the same framework, with fifty million dollars behind it. The federal position explains why neither of them changes what a Kentucky physician may do.